STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

Srivastava, Raghvendra MJie, Hyun-baeFerrone, SoldanoFerris, Robert L2014-07-072013Srivastava, Raghvendra M, Hyun-bae Jie, Soldano Ferrone, and Robert L Ferris. 2013. “STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients.” Journal for Immunotherapy of Cancer 1 (Suppl 1): P175. doi:10.1186/2051-1426-1-S1-P175. http://dx.doi.org/10.1186/2051-1426-1-S1-P175.2051-1426http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407007en-USSTAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patientsOther2014-07-0710.1186/2051-1426-1-S1-P175